（一）会计师事务所基本情况 立信会计师事务所（特殊普通合伙）（以下简称"立信"）由我国会计泰斗潘 序伦博士于 1927 年在上海创建，1986 年复办，2010 年成为全国首家完成改制的 特殊普通合伙制会计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。 立信是国际会计网络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具 有证券、期货业务许可证，具有 H 股审计资格，并已向美国公众公司会计监督委 员会（PCAOB）注册登记。 江西富祥药业股份有限公司董事会审计委员会 对会计师事务所 2023 年度履职情况评估及履行监督职责情况报告 根据《公司法》《证券法》《上市公司治理准则》《国有企业、上市公司选聘 会计师事务所管理办法》《深圳证券交易所上市公司自律监管指引第 2 号——创 业板上市公司规范运作》等法律法规，现将江西富祥药业股份有限公司（以下简 称"公司"）董事会审计委员会对会计师事务所 2023 年度履职情况评估及审计委 员会履行监督职责情况的报告汇报如下： 一、2023 年年审会计师事务所基本情况 截至 2023 年末，立信拥有合伙人 278 名、注册会计师 2,533 名、从业人员 总数 ...

Financial Performance - The company's revenue for Q1 2024 was ¥340,430,593.83, a decrease of 14.45% compared to ¥397,918,173.64 in the same period last year[5] - Net profit attributable to shareholders was ¥1,468,451.11, representing a significant increase of 104.87% from a loss of ¥30,146,940.29 in the previous year[5] - The net cash flow from operating activities improved to ¥72,636,084.28, a 176.59% increase from a negative cash flow of ¥94,831,724.81 in the same period last year[5] - The net profit margin improved significantly, with net profit increasing by 97.80% from a loss of ¥33,590,833.08 to a loss of ¥739,909.51[9] - Operating profit for Q1 2024 was 4,102,182.37 CNY, compared to a loss of -33,802,386.93 CNY in Q1 2023[32] - The total profit before tax for Q1 2024 was 3,828,411.93 CNY, compared to a loss of -33,579,518.89 CNY in the same quarter last year[32] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,712,465,475.11, down 2.21% from ¥4,819,038,871.49 at the end of the previous year[5] - Total liabilities decreased to CNY 2,238,808,080.28 from CNY 2,348,298,828.04, a reduction of 4.7%[29] - The company's cash and cash equivalents at the end of Q1 2024 were CNY 668,334,470.25, down from CNY 729,371,363.68 at the beginning of the quarter, a decline of 8.4%[27] - Accounts receivable decreased to CNY 254,315,430.17 from CNY 274,194,730.73, representing a reduction of 7.2%[27] - Inventory increased slightly to CNY 435,841,522.61 from CNY 434,677,632.23, showing a marginal increase of 0.3%[27] Shareholder Information - The total number of common shareholders at the end of the reporting period is 21,737[11] - The largest shareholder, Bao Jianhua, holds 19.28% of the shares, amounting to 106,049,808 shares, with 33,530,000 shares pledged[11] - The company repurchased 11,355,900 shares, representing 2.06% of the total share capital[12] - The top ten shareholders collectively hold significant stakes, with the largest holding being 19.28%[11] - The company has a total of 6,679,252 shares held by Jiangxi Guokong Financial Development Co., Ltd., accounting for 1.21% of the total share capital[13] Operational Efficiency - The company reported a significant reduction in sales expenses by 73.79%, from ¥8,988,432.14 to ¥2,355,625.15, attributed to decreased market development costs[9] - The company experienced a 44.28% increase in tax and additional charges, totaling ¥4,783,074.12, due to higher urban construction tax and education fees[9] - Total operating costs decreased to CNY 347,981,386.08, down 19.3% from CNY 431,474,684.77 year-over-year[31] - Research and development expenses for the quarter were CNY 15,874,928.96, down 18.4% from CNY 19,477,717.76 in the previous year[31] Strategic Initiatives - The company aims to solidify its position in the pharmaceutical sector while expanding into lithium battery electrolyte additives and synthetic biology microbial protein businesses[17] - The company plans to enhance its core competitiveness in pharmaceutical products and increase market share and gross profit margins[18] - The company is focused on optimizing its production operations and improving efficiency through lean manufacturing and smart manufacturing initiatives[19] - Cost control will be emphasized across the entire industry chain to enhance product competitiveness and improve operational efficiency[20] - The company is committed to improving safety management and establishing a robust safety culture within its operations[22] - Compliance management will be strengthened to enhance corporate governance and support high-quality development[23] - The company will prioritize investor protection, particularly for small and medium-sized investors, in line with regulatory policies[24] Cash Flow and Investment - The company reported a decrease in investment cash outflows by 80.75%, from -¥214,650,007.57 to -¥41,323,477.94, indicating reduced investment payments during the period[9] - Investment activities resulted in a net cash outflow of -41,323,477.94 CNY, an improvement from -214,650,007.57 CNY in the previous year[35] - Financing activities generated a net cash outflow of -57,570,807.00 CNY, compared to a net inflow of 82,535,602.13 CNY in Q1 2023[35]

江西富祥药业股份有限公司 开展外汇套期保值业务可行性分析报告 一、开展外汇套期保值业务的目的 江西富祥药业股份有限公司（以下简称"公司"）为有效规避外汇市场的风 险，防范汇率大幅波动对公司造成不良影响，公司遵循稳健原则，在不影响公司 主营业务发展和资金使用安排的前提下，与金融机构适度开展外汇套期保值业务。 该交易业务以"保值"而非"增值"为外汇风险核心管理目标，遵循套期保值原 则，不进行投机和单纯套利交易。 二、开展外汇套期保值业务的基本情况 （一）交易金额 随着公司资产规模及业务需求情况，公司及子公司拟开展的外汇套期保值业 务在审批有效期内任一时点交易金额（含前述交易的收益进行再交易的相关金额） 不超过 5 亿元人民币或等值外币。该额度可以循环滚动使用。 （二）交易方式 1、交易品种：公司拟开展的外汇套期保值业务交易品种包括远期结售汇、 外汇掉期、外汇期权、利率互换、利率掉期、利率期权等单一品种或者上述产品 的组合。 （三）交易期限 上述额度自公司 2023 年年度股东大会审议通过之日起 12 个月内有效，资金 在上述额度和期限范围内可循环滚动使用。如单笔交易的存续期超过了授权期限， 则授权期限自动顺延至该 ...

证券代码：300497 证券简称：富祥药业 公告编号：2024-041 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司 江西富祥药业股份有限公司（以下简称"公司"）于2024年4月26日召开了第四 届董事会第二十次会议，审议通过了《关于延长以简易程序向特定对象发行股票决议 有效期及相关授权有效期的议案》，董事会同意提请股东大会延长以简易程序向特定 对象发行股票决议有效期及相关授权有效期，上述议案尚需提交公司股东大会审议。 现将具体情况公告如下： 公司分别于2023年4月24日、2023年5月17日召开第四届董事会第九次会议和2022 年年度股东大会，审议通过了《关于提请股东大会授权董事会办理以简易程序向特定 对象发行股票的议案》。且于2023年12月4日召开第四届董事会第十六次会议，审议 通过《关于公司符合以简易程序向特定对象发行股票条件的议案》等相关议案，于2024 年3月22日召开第四届董事会第十九次会议，审议通过《关于公司2023年度以简易程 序向特定对象发行股票竞价结果的议案》等相关议案。 根据前述股东大会决议，公司本次发行相 ...

长江证券承销保荐有限公司 关于江西富祥药业股份有限公司 2023 年度募集资金存放与使用情况的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"）作为江西富祥药业股份 有限公司（以下简称"富祥药业"或"公司"）持续督导之保荐机构，根据《证券发 行上市保荐业务管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳证券 交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关规 定，对富祥药业 2023 年度募集资金存放与使用情况进行了核查，核查情况及意 见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准江西富祥药业股份有限公司公开发行 可转换公司债券的批复》（证监许可〔2019〕68 号）核准，公司于 2019 年 3 月 1 日公开发行可转换公司债券 420 万张，每张面值 100 元，募集资金总额为人民币 420,000,000.00 元，扣除发行费用 8,016,144.42 元后，本次募集资金净额为 411,983,855.58 元。以上募集资金已由立信会计师事务所（特殊普通合伙）于 2019 年 3 月 8 日出具信会师报字〔2019〕第 ZF10054 号《认购 ...

证券代码：300497 证券简称：富祥药业 公告编号：2024-040 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要内容提示： 1、交易品种：包括远期结售汇、外汇掉期、外汇期权、利率互换、利率掉期、 利率期权等单一品种或者上述产品的组合。 2、交易金额：在任一时点交易金额不超过人民币5亿元（或等值货币）额度范围 内开展外汇套期保值业务，该额度自2023年年度股东大会审议后12个月内有效，在审 批权限内可循环滚动使用。 3、特别风险提示：公司开展外汇套期保值交易遵循合法、谨慎、安全和有效的 原则，以规避和防范汇率风险为目的，但外汇衍生品交易操作仍存在一定的汇率波动 风险、内部控制风险和交易违约风险等。敬请投资者注意投资风险。 江西富祥药业股份有限公司（以下简称"公司"）于2024年4月26日召开第四届 董事会第二十次会议和第四届监事会第十三次会议，审议通过了《关于开展外汇套期 保值业务的议案》，同意公司及合并报表范围内的子公司根据海外业务的发展情况， 在不超过人民币5亿元（或等值外币）的额度内开展外汇套期保值业务，上述额度自 2023年年度股东大会审议通 ...

Financial Performance - The company reported a revenue of RMB 1.2 billion for the year 2023, representing a year-on-year growth of 15%[29]. - The company achieved a net profit of RMB 300 million, reflecting a net profit margin of 25%, consistent with industry standards[30]. - The company reported a revenue of CNY 1,609,669,988.35 in 2023, a decrease of 2.28% compared to CNY 1,647,263,426.90 in 2022[37]. - The net profit attributable to shareholders was CNY -200,800,049.29, representing a decline of 41.94% from CNY -141,471,326.16 in the previous year[37]. - The total revenue for 2023 was approximately ¥1.61 billion, a decrease of 2.28% compared to ¥1.65 billion in 2022[103]. - The company experienced a net loss of 68,648,418.74 during the reporting period[149]. - The company reported a significant operating loss of 52,922,217.04, reflecting challenges in the current market environment[148]. Market Expansion and Product Development - The company plans to deepen its pharmaceutical business, expand market share, and enhance the supply chain for lithium battery electrolyte additives to improve profitability[9]. - The company aims to explore the field of synthetic biological microbial protein products, with plans to deliver existing orders and expand into new markets[9]. - The company plans to launch three new products in the β-lactam antibiotic category in 2024, aiming for a market share increase of 10%[30]. - Future guidance estimates a revenue growth of 12% to 15% for 2024, driven by new product launches and market expansion efforts[29]. - The company is exploring potential acquisitions to enhance its product portfolio and market presence, with a budget of RMB 300 million allocated for this purpose[30]. - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in international sales by 2025[191]. - The company is actively pursuing partnerships with research institutions to accelerate the development of new technologies and products[191]. Research and Development - The company plans to invest in R&D to enhance product innovation and maintain competitiveness in the pharmaceutical sector[15][16]. - The company is investing RMB 200 million in R&D for innovative drug formulations and production technologies[30]. - The company increased R&D investment by approximately 20 million yuan to enhance its core competitiveness in microbial protein[59]. - R&D investment amounted to ¥97,453,168.04 in 2023, representing 6.05% of operating revenue, an increase from 4.70% in 2022[119]. - The company has received a patent acceptance notice for its new microbial strains used in protein production, indicating progress in its R&D efforts[82]. - The company has achieved significant progress in R&D, with several projects like Tor and MSF in the process of registration approval, which will further enrich its product offerings[117]. Operational Efficiency and Cost Management - The company is focusing on optimizing production processes and improving automation to reduce raw material consumption and enhance production efficiency[9]. - The company has implemented cost reduction and efficiency improvement measures through process optimization and technological innovation[50]. - The company is focused on optimizing its production operations and improving organizational efficiency through lean manufacturing and smart manufacturing initiatives[153]. - Cost control measures will be implemented across the entire industry chain to enhance product competitiveness and improve efficiency[154]. - The company aims to enhance operational efficiency, targeting a 5% reduction in production costs through process optimization[191]. Compliance and Governance - The company emphasizes safety production management as a foundation for sustainable development and economic benefits[155]. - Compliance management is prioritized to enhance the company's soft power and overall competitiveness, ensuring adherence to relevant laws and regulations[157]. - The company is committed to protecting the legitimate rights and interests of investors, particularly small and medium-sized investors, in line with regulatory policies[158]. - The company is focused on enhancing its governance structure by ensuring compliance with the regulations regarding independent directors, which is crucial for maintaining investor confidence[178]. - The company is committed to adhering to legal regulations and corporate governance standards in its operations[197]. Shareholder Engagement and Management Changes - The company held four temporary shareholder meetings and one annual shareholder meeting in 2023, with investor participation rates of 21.72%, 25.45%, 23.05%, 7.26%, and 19.41% respectively[173]. - The board of directors increased its membership from 7 to 8 members in February 2023, and later adjusted back to 7 members in December 2023, maintaining compliance with legal requirements[166]. - The company has established specialized committees within the board to enhance decision-making capabilities[166]. - The company is likely to continue focusing on governance and compliance as part of its broader strategy to enhance shareholder value and market position[180]. - The company has undergone several management changes, including the election of Li Huiyue as vice chairman on February 22, 2023, and the appointment of Chen Yinghui as deputy general manager on March 3, 2023, both for operational development needs[179]. Challenges and Risks - The pharmaceutical segment faced high raw material prices, squeezing profit margins, while some product prices decreased year-on-year due to intensified market competition[7]. - The company acknowledges risks related to market competition, environmental regulations, and raw material price fluctuations, which could impact operations[12][13][17]. - The company anticipates challenges due to increased market competition and global economic slowdown, but is focused on seizing opportunities for future growth[49].

长江证券承销保荐有限公司 关于江西富祥药业股份有限公司 开展外汇套期保值业务的核查意见 作为江西富祥药业股份有限公司(以下简称"富祥药业"或"公司")持续督导的 保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司 自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》 等文件的规定，长江证券承销保荐有限公司(以下简称"长江保荐"或 "保荐机构") 对富祥药业开展外汇套期保值业务的事项进行了核查，具体核查情况如下： 一、本次开展外汇套期保值业务的交易情况概述 （一）交易目的 为有效规避外汇市场的风险，防范汇率大幅波动对公司造成不良影响，公司 遵循稳健原则，在不影响公司主营业务发展和资金使用安排的前提下，与金融机 构适度开展外汇套期保值业务。该交易业务以"保值"而非"增值"为外汇风险 核心管理目标，遵循套期保值原则，不进行投机和单纯套利交易。 （二）交易金额 随着公司资产规模及业务需求情况，公司及子公司拟开展的外汇套期保值业 务在审批有效期内任一时点交易金额（含前述交易的收益进行再交易的相关金额） ...

一、公司2023年利润分配预案 经立信会计师事务所有限公司（特殊普通合伙）审计，公司（合并口径）2023年 度实现净利润-223,256,092.68元，母公司2023年度实现净利润-65,272,907.27元。截至 2023年12月31日，公司（合并口径）资本公积余额为1,414,476,825.77元，累计未分配 利润总额536,616,494.96元，母公司累计未分配利润总额740,696,621.05元。 根据《公司章程》的有关规定，结合公司实际情况，2023年度利润分配预案为： 不派发现金红利，不送红股，不以公积金转增股本。 二、2023 年度拟不进行分配利润的原因 证券代码：300497 证券简称：富祥药业 公告编号：2024-032 江西富祥药业股份有限公司 关于2023年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 江西富祥药业股份有限公司（以下简称"公司"）于2024年4月26日召开了第四 届董事会第二十次会议和第四届监事会第十三次会议，审议通过了《关于2023年度利 润分配预案的议案》，本议案尚需提交公司股东大会审 ...

长江证券承销保荐有限公司 关于江西富祥药业股份有限公司 2023 年度持续督导跟踪报告 | 保荐机构名称：长江证券承销保荐有限公司 | 被保荐公司简称：富祥药业 | | --- | --- | | 保荐代表人姓名：王海涛 | 联系电话：010-57065285 | | 保荐代表人姓名：梁国超 | 联系电话：021-61118978 | 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2．督导公司建立健全并有效执行规章制度 | | | 的情况 | | | （1）是否督导公司建立健全规章制度（包 | 是 | | 括但不限于防止关联方占用公司资源的制 | | | 度、募集资金管理制度、内控制度、内部审 | | | 计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 2 次 | | （2）公司募集资金项目进展是否与信息披 | 是 | | ...